According to The Insight Partners market research study titled ‘Perfusion Systems Market – Global Analysis and Forecasts by Type, Component, the global perfusion systems market is expected to reach US$ 1,442.28 Mn in 2027 from US$ 1,044.75 Mn in 2018. The market is estimated to grow with a CAGR of 3.8% from 2019-2027. The report highlights the trends prevalent in the global perfusion systems market and the factors driving the market along with those that act as deterrents to its growth.
Download Sample PDF Perfusion Systems Report Copy at: https://www.theinsightpartners.com/sample/TIPMD00002293/
The perfusion systems market by type is segmented into bioreactor perfusion systems, microfluidic perfusion systems, gravity or pressure driven perfusion systems, and small mammal organ perfusion systems. In 2018, the bioreactor perfusion systems segment held a largest market share of 44.3% of the perfusion systems market, by type. This segment is also expected to dominate the market in 2027 owing to increasing production by the biopharmaceutical and pharmaceutical and its advantages including, high quality of product, product stability, and scalability. Moreover, the microfluidic perfusion systems segment is anticipated to witness the significant growth rate of 3.9% during the forecast period, 2019 to 2027 owing to increasing application of basic cell biology, molecular biological assays, tissue engineering, and systems biology.
Key factors driving the market are rising prevalence of cardiovascular diseases, significant growth of pharmaceutical and biotechnology industries, rising need for the organ transplantation, and rising cell based research activities. However, factors such as expensive organ transplant surgeries, and limited numbers of donors for organ transplant surgeries are likely to restrain the market growth to a certain extent.
Some of the prominent players operating in perfusion systems market are REPLIGEN CORPORATION, Merck KGaA, Ala Scientific Instruments, Inc., XVIVO Perfusion, Medtronic, XENIOS AG (Fresenius Medical Care AG & Co. KGaA), Getinge AB, TERUMO CORPORATION, LivaNova PLC, Sartorius AG, Harvard Bioscience, RAND, Sanisure (Sani-Tech West, Inc.), AutoMate Scientific, Inc., Jobst Technologies GmbH, APD (Advanced Perfusion Diagnostics), Spectrum Medical, Transonic Systems Inc, OrganOx, ISCHEMAVIEW, INC, and CESCO BIOENGINEERING CO., LTD. The market players are focused towards bringing new and innovative products to sustain their position in the market. For instance, in March 2018, Sartorius Stedim Biotech (Sartorius AG) launched ambr 250 high throughput (ht) perfusion, specially designed for rapid cell culture perfusion process development to optimize production of therapeutic antibodies. The developments performed by the companies are helping the market to grow in the coming years.
Rising Need for The Organ Transplantation is expected to boost the market growth over the years
Organ transplantation is a surgical process done when a patient’s organ has stopped functioning completely. The organ transplant is commonly done for the organs such as heart, liver and kidney. However, the rising cases of the chronic diseases are leading to the need of the transplantation for the other organs such as lung, pancreases, cornea, and vascular tissues among others. The organ transplantation surgeries are rising across the world. For instance, in Spain, approximately 5,260 transplant surgeries were performed, among which nearly 3,200 were kidney transplant and around 1,200 were liver transplant surgeries. The number of heart transplant surgeries were approximately 300 and lung were nearly 360. The public-private partnership in assistance with the transplant coordinators has enormously contributed to the improvement of the organ transplantation.
As per the National Chronic Kidney Disease fact sheet 2017, states that approximately, 30 million people in US are estimated to have chronic kidney diseases. Similarly, according to the National Institute id Diabetes and Digestive and Kidney Diseases states that nearly 661,000 Americans have kidney failure among these nearly, 468,000 patients are taking dialysis, and approximately 193,000 have undergone kidney transplantation. Therefore, the increasing incidences are likely to grow more needs for the kidney transplantation in the coming years. Likewise, it is estimated that the growing numbers of the heart diseases are also responsible to drive the market in coming futures.
Rising Cell Based Research Activities
The rise in the chronic diseases, advantages of the applications of biotechnology are growing the extensive cell based research activities. The cell based assays assists in understanding the challenges of biology of the living organisms. The cell based assays helps in the understanding the aspects such as cell signaling, proliferation, apoptosis, cellular genetics, neurology, cancer and more. The cell based assays are extensively carried out in pharmaceutical, biotechnology industries, research institutes and academics research institutes. The pharmaceutical and biopharmaceutical industries need to efficiently commercialize the drug. Therefore, cell based assays in the pharmaceutical and biotechnology industry are the driving factor for the growth of the perfusion systems.
The cell based assays are also extensively carried out by the contract research organization for the clinical trial studies and other processes. The chronic diseases such as cancer and other genetic related studies are enforcing for the cell based studies. For instance, Charles River offers services for the human primary cell based assays and according to an article published by the company states that the development in the cell based assays are likely to continue growing in the future.
The report segments the global perfusion systems market as follows:
Global Perfusion Systems Market – By Type
Global Perfusion Systems Market – By Component
Global Perfusion Systems Market – By Geography
Buy Complete Perfusion Systems Report at: https://www.theinsightpartners.com/buy/TIPMD00002293/